Experiences with iohexol and iodixanol during cardioangiography in an unselected patient population.
OBJECTIVE
To compare the frequency of adverse events after cardioangiography with iohexol and iodixanol in an unselected patient population with special regard to previously defined "risk patients": age> or =65 years, severe coronary artery disease, unstable angina pectoris and left ventricular dysfunction.


METHODS
A total of 1020 patients referred to cardioangiography were included in this open, prospective cross-sectional study, comparing iodixanol (320 mgI/ml) and iohexol (350 mgI/ml). Adverse events were recorded and the patients answered a questionnaire.


RESULTS
Cardiac adverse events (CAE) i.e., angina pectoris, arrhythmia and dyspnea within 24 h of examination were reported by 9% of patients receiving iohexol and by 7% receiving iodixanol. Two cases of ventricular fibrillation occurred, both after iohexol. The proportion of CAE was 11% for patients> or =65 years receiving iohexol and 7% in younger patients. For patients receiving iodixanol the proportion was 7%, in both age groups. Patients with severe coronary disease had more CAE than less ill patients in both CM groups. The proportion of unstable patients with CAE was 18% in the iohexol group and 12% in the iodixanol group. Left ventricular dysfunction was not related to CAE.


CONCLUSIONS
Iodixanol could be advantageous in patients with unstable angina.
Flinck
A
A
Department of Radiology, Göteborg University, Sahlgrenska University Hospital, SE 413 45 Göteborg, Sweden. agneta.flinck@xray.gu.se
Gottfridsson
B
B
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000787:Angina Pectoris / Q000150:complications; D003287:Contrast Media / Q000009:adverse effects*; D017023:Coronary Angiography / Q000009:adverse effects*; D003430:Cross-Sectional Studies; D005260:Female; D006406:Hematoma / Q000139:chemically induced; D006801:Humans; D007472:Iohexol / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011795:Surveys and Questionnaires; D013997:Time Factors; D014283:Triiodobenzoic Acids / Q000009:adverse effects*; D014672:Vectorcardiography / Q000009:adverse effects; D014693:Ventricular Fibrillation / Q000139:chemically induced
D003287:Contrast Media; D014283:Triiodobenzoic Acids; D007472:Iohexol; C044834:iodixanol